Revance Therapeutics
Stock Forecast, Prediction & Price Target
Revance Therapeutics Financial Estimates
Revance Therapeutics Revenue Estimates
Revance Therapeutics EBITDA Estimates
Revance Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $77.79M N/A | $132.56M 70.39% | $234.04M 76.54% | Avg: $372.29M Low: $349.42M High: $407.88M avg. 59.07% | Avg: $474.55M Low: $447.57M High: $510.26M avg. 27.46% | Avg: $596.05M Low: $562.15M High: $640.89M avg. 25.60% | Avg: $724.44M Low: $683.25M High: $778.95M avg. 21.54% |
Net Income
% change YoY
| $-286.82M N/A | $-356.42M -24.26% | $-323.98M 9.10% | Avg: $-89.82M Low: $-109.97M High: $-49.06M avg. 72.27% | Avg: $-18.66M Low: $-64.29M High: $27.91M avg. 79.22% | Avg: $74.97M Low: $69.43M High: $82.30M avg. 501.73% | Avg: $125.63M Low: $116.34M High: $137.91M avg. 67.55% |
EBITDA
% change YoY
| $-261.11M N/A | $-241.61M 7.46% | $-290.63M -20.29% | Avg: $-363.70M Low: $-398.46M High: $-341.36M avg. -25.14% | Avg: $-463.60M Low: $-498.48M High: $-437.24M avg. -27.46% | Avg: $-582.29M Low: $-626.10M High: $-549.18M avg. -25.60% | Avg: $-707.72M Low: $-760.97M High: $-667.48M avg. -21.54% |
EPS
% change YoY
| -$4.25 N/A | -$4.9 -15.29% | -$3.83 21.83% | Avg: -$0.89 Low: -$1.3 High: -$0.58 avg. 76.86% | Avg: -$0.14 Low: -$0.76 High: $0.33 avg. 84.19% | Avg: $0.89 Low: $0.82 High: $0.97 avg. 733.03% | Avg: $1.49 Low: $1.38 High: $1.63 avg. 67.55% |
Operating Expenses
% change YoY
| $329.06M N/A | $353.06M 7.29% | $398.65M 12.91% | Avg: $12.32B Low: $11.56B High: $13.50B avg. 2992.10% | Avg: $15.71B Low: $14.81B High: $16.89B avg. 27.46% | Avg: $19.73B Low: $18.61B High: $21.22B avg. 25.60% | Avg: $23.98B Low: $22.62B High: $25.79B avg. 21.54% |
FAQ
What is Revance Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 180.19% in 2025-2028.
We have gathered data from 4 analysts. Their low estimate is -109.97M, average is -89.82M and high is -49.06M.
What is Revance Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 33.42% in 2025-2028.
We have gathered data from 9 analysts. Their low revenue estimate is $349.42M, average is $372.29M and high is $407.88M.
What is Revance Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 240.41% in 2025-2028.
We have gathered data from 4 analysts. Their low earnings per share estimate is -$1.3, average is -$0.89 and high is $-0.58.
What is the best performing analyst?
In the last twelve months analysts have been covering Revance Therapeutics stock. The most successful analyst is David Amsellem.